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Objectives: To characterize a novel ceftazidime-hydrolysing CTX-M mutant, designated CTX-M-54,
produced by Klebsiella pneumoniae clinical isolate BDK0419 and to investigate its genetic environment.
Methods:Antimicrobial susceptibilities were determined by disc diffusion and agar dilutionmethods, and
the double-disc synergy test was carried out. Detection of genes encoding class A b-lactamases was
performed by PCR amplification, and the genetic organization of the blaCTX-M-54 gene was investigated
by PCR and sequencing of the regions surrounding this gene. Kinetic parameters were determined from
purified CTX-M-54.
Results:The strain BDK0419 contained a transferable plasmidwith amolecular size of21 kbp that carries
both blaSHV-2a and bla CTX-M-54 b-lactamase genes, along with two other plasmids. The blaCTX-M-54 gene
was flanked upstream by an ISEcp1 insertion sequence and downstream by an IS903-like element.
CTX-M-54 had a P167Q substitution within the omega loop region of class A b-lactamases compared
with the sequence of CTX-M-3. The MIC of ceftazidime for K. pneumoniae BDK0419 was 16-fold higher
than that of cefotaxime; however, the kinetic parameter of CTX-M-54 against ceftazidime revealed a
low catalytic efficiency.
Conclusions: This work shows once again that novel CTX-M enzymes with an expanded activity
towards ceftazidime through a single amino acid substitution can be identified from clinical isolates.
Thus, detection of CTX-M enzymes can no longer be based solely on the resistance phenotypes of
clinical isolates towards ceftazidime and cefotaxime.
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Introduction
CTX-M-type extended-spectrum b-lactamases (ESBLs), the most
widespread enzymes among non-TEM and non-SHV plasmid-
mediated ESBLs, were initially reported in the second half of
the 1980s in Europe.1 As the designation ‘CTX’ indicates, these
enzymes preferentially hydrolyse cefotaxime but not ceftazidime.
However, there have been recent reports of CTX-M mutants
exhibiting a significant hydrolytic activity against ceftazidime.
Amino acid substitutions at positions 167 and 240 (Ambler’s
numbering scheme) in CTX-M-type enzymes have been associ-
ated with expansion of activity towards ceftazidime. CTX-M-15,
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CTX-M-16 and CTX-M-27 harbour an Asp!Gly substitution
at position 240.2–4 CTX-M-19 (derived from CTX-M-18) and
CTX-M-23 (derived from CTX-M-19) harbour a Pro!Ser
and a Pro!Thr substitution at position 167 in the omega
loop, respectively.5,6
This report identifies another ceftazidime-hydrolysing CTX-M
mutant, designated CTX-M-54. CTX-M-54 differed from CTX-
M-3 only by the substitution Pro-167!Gln and is the third CTX-
M enzyme harbouring an amino acid substitution at position 167
after CTX-M-19 and CTX-M-23.
Materials and methods
Bacterial strains
Klebsiella pneumoniae clinical isolate BDK0419 was identified with
the API 20E system (bioMe´rieux, Marcy l’Etoile, France).
Escherichia coli BL21(DE3) was the host for cloning experiments,
and E. coli J53 AzideR was used as a recipient strain for conjugative
transfer. E. coli ATCC 25933 was used as an MIC reference strain.
Antimicrobial susceptibility testing
Antibiotic-containing discs (BBL, Cockeysville, MD, USA) were
used for routine antibiograms by disc diffusion assay according to
the recommendations of the CLSI.7 The double-disc synergy test
was carried out on Mueller–Hinton agar (Difco Laboratories, Detroit,
MI, USA) with discs of ceftazidime, cefotaxime and aztreonam,
each containing 30 mg of the drug, placed at distances of 20 mm
(centre to centre) from a disc containing amoxicillin–clavulanic acid
(20 mg/10 mg) in the centre of the plate.8 MICs were determined by
the agar dilution method with Mueller–Hinton agar with an inoculum
of 104 cfu.9 MICs of b-lactams were determined alone or in com-
bination with a fixed concentration of clavulanic acid (4 mg/L).
PCR experiments
Plasmid DNA of K. pneumoniae BDK0419 was extracted as
described previously,10 and this DNA was used as a template
in PCR experiments with a series of primers designed for the detec-
tion of class A b-lactamase genes and their extended-spectrum
derivatives: blaTEM, blaSHV, blaCTX-M-1, blaCTX-M-2, blaCTX-M-8,
blaCTX-M-9, blaPER-1, blaVEB-1, blaIBC/GES and blaTLA (Table 1).
The PCR products were subjected to direct sequencing by the
dideoxynucleotide chain-termination method with an automatic
DNA sequencer (ABI 3700, Perkin-Elmer, Foster City, CA,
USA). Both strands of the PCR products were sequenced twice.
The genetic organization of the blaCTX-M-54 gene was investigated
by PCR and sequencing of the regions surrounding this gene. The
internal ISEcp1 forward primers (TN1-F and BTN-F) and CTX-M-1
reverse primers (CTX-M-1R and FM-1R) were used to investigate
the promoter regions of the blaCTX-M-54 gene. PCR primers
corresponding to sequences upstream (pemK and ISEcp1) and down-
stream (IS903) of the blaCTX-M-54 gene were also used (Table 1).
Table 1. Sequences of the primers used in the study
PCR target Primer name Primer sequence
blaCTX-M (CTX-M-1 cluster) CTX-M-1F 5
0-CCGTCACGCTGTTGTTAGG-30
CTX-M-1R 50-GACGATTTTAGCCGCCGAC-30
BM-1F 50-ACTATGGCACCACCAACGAT-30
FM-1R 50-TTCGGTTCGCTTTCACTTTT-30
blaCTX-M (CTX-M-2 cluster) CTX-M-2F 5
0-CGG TGC TTA AAC AGA GCG AG-30
CTX-M-2R 50-CCA TGA ATA AGC AGC TGA TTG CCC-30
blaCTX-M (CTX-M-8 cluster) CTX-M-8F 5
0-ACG CTC AAC ACC GCG ATC-30
CTX-M-8R 50-CGT GGG TTC TCG GGG ATA A-30
blaCTX-M (CTX-M-9 cluster) CTX-M-9F 5
0-GAT TGA CCG TAT TGG GAG TTT-30
CTX-M-9R 50-CGG CTG GGT AAA ATA GGT CA-30
blaPER-1 PER-1F 5
0-GTT AAT TTG GGC TTA GGG CAG-30
PER-1R 50-CAG CGC AAT CCC CAC TGT-30
blaVEB VEB-F 5
0-ACC AGA TAG GAG TAC AGA CAT ATG A-30
VEB-R 50-TTC ATC ACC GCG ATA AAG CAC-30
blaGES and blaIBC GES/IBC-F 5
0-GTT AGA CGG GCG TAC AAA GAT AAT-30
GES/IBC-R 50-TGT CCG TGC TCA GGA TGA GT-30
blaTLA TLA-F 5
0-CGC GAA AAT TCT GAA ATG AC-30
TLA-R 50-AGG AAA TTG TAC CGA GAC CCT-30
pemK PK-F 50-AGGGGAAATCTGGCTTGTCT-30
PK-R 50-TCTGTCGAAACAATGGGTCA-30
ISEcp1 TN1-F 50-TCTGCTCCTTGAGAATGCAA-30
TN1-R 50-TCGCCCAAAATGACTTTAGC-30
BTN-F 50-CGGTGGGTCATCTCTTGCTA-30
FTN-R 50-TAATTCGTCGCAAAATGCAA-30
IS903 IS9-F 50-TGGCCCACCTACAATAAAGC-30
IS9-R 50-GGCATACCTGCTTTCGTCAT-30
FIS9-R 50-TGCCTCGTGAAGAAGGTGTT-30
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Mating-out assays
Conjugation experiments were carried out between K. pneumoniae
BDK0419 (donor) and azide-resistant recipient strain E. coli J53
on Mueller–Hinton agar plates.11 Transconjugants were selected
on Mueller–Hinton agar plates supplemented with ceftazidime
(2 mg/L) and sodium azide (100 mg/L).
Purification of CTX-M-54 b-lactamase
The PCR product obtained with primers CTX-M-54 pcrF (50-GG
GAA TTC CAT ATG GTT AAA AAA TCA CTG CG-30; NdeI
site underlined) and CTX-M-54 pcrR (50-CCG CTC GAG CAA
ACC GTC GGT GAC GAT TTT-30; XhoI site underlined) was
purified with a QIAquick column (Qiagen, Courtaboeuf, France)
and ligated in the NdeI and XhoI sites of plasmid pET30a (Novagen,
Milan, Italy). It was then subjected to confirmatory sequencing. The
expression vector constructed, named pET30a-CTX-M-54, was intro-
duced into E. coli BL21(DE3) competent cells. E. coli BL21(DE3)
carrying plasmid pET30a-CTX-M-54 was cultured at 37C in 1 L of
LB broth supplemented with kanamycin (50 mg/L). Isopropyl-b-D-
thiogalactopyranoside (final concentration, 0.4 mM) was added when
the culture reached an OD600 of 0.6, and the culture was incubated
overnight at 20C. The cells were harvested by centrifugation and
were resuspended in 50 mL of buffer A [50 mM Tris (pH 7.0), 500
mM NaCl, 10 mM imidazole] and were then disrupted by microflu-
idizer at 15 000 psi. The cell lysate was finally centrifuged at 15 000
g for 40 min to remove cell debris. The cleared supernatant was
loaded onto an Ni-NTA column (XK16, Amersham-Pharmacia-Bios-
ciences, Milan, Italy) pre-equilibrated with buffer A. After loading,
buffer B [50 mM Tris (pH 7.0), 500 mM NaCl, 25 mM imidazole]
was used to wash the column. The b-lactamase was eluted with a
linear gradient of imidazole (25–300 mM in 1 h). The fractions
containing nitrocefin-hydrolysing activity and purity-confirmed by
SDS–PAGE were pooled and dialysed with buffer C [50 mM Tris
(pH 7.0), 300 mM NaCl without imidazole]. The final protein con-
centration was 0.315 mg/mL (purity >>90%).
Isoelectric focusing (IEF)
To determine the isoelectric point (pI), 5 mL of the condensed super-
natant containing b-lactamase was loaded onto a Novex IEF Gel
(pH 3-10; Invitrogen, Carlsbad, CA, USA) with an Xcell surelock
Mini-Cell system (Invitrogen). Running conditions were 100 V con-
stant for 1 h, 200 V constant for 1 h and 500 V for 30 min.11 The pI
of the b-lactamase was measured by staining the gel with a 0.05%
solution of nitrocefin (Oxoid, Basingstoke, UK).
Kinetic measurements
Purified b-lactamase was used for kinetic measurements performed
at 30C with 100 mM sodium phosphate buffer (pH 7.0) with a Cary
300 Bio UV-visible spectrophotometer (Varian Inc., Palo Alto, CA,
USA). Wavelengths of 235 nm for benzylpenicillin (Sigma, St Louis,
MO, USA); 236 nm for ampicillin (Sigma); 318 nm for aztreonam
(Sigma); 482 nm for nitrocefin (Oxoid); 260 nm for ceftazidime
(Sigma), cefotaxime and cefuroxime (Sigma); 265 nm for cefalothin
(Sigma); and 260 nm for cefaloridine (Sigma) were used. Extinction
coefficients of each antibiotic substrate used in the spectro-
photometric assays were same as described previously.4 The
steady-state kinetic parameters (Km and kcat) were determined
under initial-rate conditions using Lineweaver–Burk plot.
Nucleotide sequence accession number
The nucleotide sequence data reported in this paper are available in
the GenBank nucleotide database under accession number
DQ303459.
Results
Description of the clinical isolate
K. pneumoniae BDK0419 was isolated from a sputum specimen
of a female patient hospitalized at an intensive care unit in a
tertiary-care hospital in Sungnam, Korea, in May 2004, for
hypertensive intracranial haemorrhage and pulmonary oedema.
Strain BDK0419 exhibited resistance to ampicillin, ampicillin–
sulbactam, piperacillin, ceftazidime, amikacin, gentamicin and
tobramycin and susceptibility to piperacillin-tazobactam,
cefoxitin, cefotaxime, cefepime, aztreonam, imipenem, cipro-
floxacin and trimethoprim/sulfamethoxazole. The strain exhibited
a positive double-disc synergy test, thus indicating the production
of ESBLs.
PCR and sequencing of the b-lactamase genes
PCR amplifications using primers specific for ESBL-encoding
genes revealed that K. pneumoniae BDK0419 possessed both
blaSHV and blaCTX-M-1-type genes. Sequence of the blaSHV
PCR amplicon with K. pneumoniae BDK0419 was 100%
identical to the blaSHV-2a sequence. Sequence data of the
blaCTX-M-1-type gene indicate an open reading frame of 873 bp,
corresponding to a putative protein of 291 amino acids. The
blaCTX-M-1-type gene differed from blaCTX-M-3, the nearest
CTX-M neighbour, by only a Pro (CCG) to Gln (CAG) sub-
stitution at Ambler position 167. As this substitution has not
previously been described in the CTX-M-type b-lactamases,
the enzyme from K. pneumoniae BDK0419 appears to be a
novel b-lactamase and has been designated CTX-M-54.
Genetic environment of blaCTX-M-54
An ISEcp1 insertion sequence, comprising an intact tnpA gene,
was located 128 bp upstream of blaCTX-M-54. ISEcp1 possesses
two imperfect inverted repeats (IRs), the left IR (IRL, CCTA-
GATTCTACGTCAGT) and the right IR (IRR, ACACACGTG-
GAATTTAGG), made of 18 bp with 14 of these 18 bp being
complementary. A putative promoter consisting of the
–10 (TACAAT) and –35 (TTGAA) regions, which drives
blaCTX-M-54 transcription, was observed within the 3
0 non-coding
sequence of ISEcp1. To identify further DNA sequences
surrounding the blaCTX-M-54 gene, several long-range PCR
pemk ISEcp1 blaCTX-M-54 IS903-like
tnpAtnpA
IRL IRR
Figure 1. Schematic map of a 4063 bp DNA fragment that contains
pemK, ISEcp1, IS903-like and the blaCTX-M-54 genes from the K. pneumoniae
BDK0419 clinical isolate. Inserted genes and their transcriptional orientation
are indicated by arrows. Two imperfect inverted repeats (IRs), the left IR
(IRL) and the right IR (IRR), of the ISEcp1 insertion sequence are represented
by ovals.
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experiments were performed using a series of primers. The
upstream region of the ISEcp1 insertion sequence contained
the pemK gene. The pemK protein, the pemK gene product, is
supposed to inhibit the growth of host cells that have lost the
pem+ plasmid.12 One-hundred and twenty-four nucleotides from
the stop codon, the blaCTX-M-54 gene was flanked by a IS903-like
element (Figure 1).
Transfer of resistance to ceftazidime
K. pneumoniae BDK0419 contained three plasmids with mole-
cular sizes of 21 (pBDK0419), 3.5 and 3 kbp. The strain trans-
ferred pBDK0419 containing both blaSHV-2a and blaCTX-M-54
genes to the E. coli J53 AzideR recipient by mating experiments.
b-Lactam susceptibility
Agar dilution MIC testing confirmed that the K. pneumoniae
BDK0419 was resistant to ampicillin and ceftazidime, inter-
mediate to aztreonam, and susceptible to cefoxitin, cefotaxime,
cefepime and imipenem (Table 2). Notably, the MIC of cef-
tazidime for this strain was 16-fold higher than that of cefo-
taxime. The b-lactam resistance phenotypes of the
transconjugant (E. coli trcBDK0419) and E. coli BL21(DE3)
carrying plasmid pET30a-CTX-M-54 were almost identical to
those of the K. pneumoniae BDK0419 (i.e. the MICs of cef-
tazidime were 16-fold higher than those of cefotaxime). Clavu-
lanic acid restored the activities of ceftazidime in all three strains.
IEF analysis
IEF of the sonic extract of E. coli trcBDK0419 showed two bands
with pI values of 7.6 and 8.0. IEF of the partially purified
b-lactamase of E. coli BL21(DE3) carrying plasmid pET30a-
CTX-M-54 revealed a band with a pI value of 8.0. The relative
molecular mass of CTX-M-54, determined by SDS–PAGE
analysis, was 28 kDa (data not shown).
Kinetic studies
The kinetic parameters for the CTX-M-54 b-lactamase showed
that it had activity against most b-lactams including benzyl-
penicillin, cefaloridine, cefuroxime and cefotaxime (Table 3).
There was a discrepancy between MIC results and the kinetic
parameters of the enzyme against ceftazidime and cefotaxime.
The catalytic efficiency (kcat/Km) of CTX-M-54 against
cefotaxime (0.2 mM–1 s–1) was higher than that against
ceftazidime (0.003 mM–1 s–1).
Discussion
The strain BDK0419 contained a transferable plasmid with a
molecular size of 21 kbp (pBDK0419) that carries both
blaSHV-2a and blaCTX-M-54 b-lactamase genes, along with two
other plasmids. CTX-M-54 had a P167Q substitution within
the omega loop region of class A b-lactamases compared with
the sequence of CTX-M-3. Amino acid substitutions at this
Table 2. MIC values of antimicrobial agents for K. pneumoniae BDK0419, E. coli trcBDK0419 and E. coli BL21(DE3) carrying plasmid
pET30a-CTX-M-54
MIC (mg/L)
Antibiotica K. pneumoniae BDK0419 E. coli trcBDK0419
E. coli BL21(DE3) carrying
plasmid pET30a-CTX-M-54
Ampicillin >256 >256 >256
Ampicillin + CLA >256 >256 >256
Cefoxitin 4 4 4
Aztreonam 16 2 4
Ceftazidime 128 128 128
Ceftazidime + CLA 16 16 16
Cefotaxime 8 8 8
Cefotaxime + CLA 1 1 1
Cefepime 1 1 1
Cefepime + CLA 0.5 0.25 0.5
Imipenem 0.25 0.25 0.25
aCLA, clavulanic acid at a fixed concentration of 4 mg/L.
Table 3. Kinetic parameters of CTX-M-54 b-lactamase against
substrates
Compound Km (mM) kcat (s–1)
kcat/Km
(mM–1s–1)
Benzylpenicillin 19 22 1.2
Cefalothin 325 11 0.03
Cefaloridine 215 145 0.7
Ampicillin 33 4 0.1
Cefotaxime 182 34 0.2
Cefuroxime 95 61 0.6
Ceftazidime 48 0.13 0.003
Nitrocefin 29 147 5.1
Aztreonam 244 9 0.04
Bae et al.
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position of CTX-M-type b-lactamases have been associated with
expansion of activity towards ceftazidime.13
MICs of ceftazidime for all K. pneumoniae BDK0419, the
transconjugant (E. coli trcBDK0419) and E. coli BL21(DE3)
carrying plasmid pET30a-CTX-M-54 were 16-fold higher than
those of cefotaxime. These results indicate that CTX-M-54 pref-
erentially hydrolyses ceftazidime but not cefotaxime. However,
the kinetic parameters of CTX-M-54 against ceftazidime revealed
a low catalytic efficiency. A similar discrepancy between MIC
results and kinetic data has been reported in CTX-M-19, ascribed
to a rapid loss of the activity of the enzyme caused by instability
of the protein.5
The blaCTX-M-54 gene was flanked upstream by an ISEcp1
insertion sequence and downstream by an IS903-like element.
The blaCTX-M genes belonging to the CTX-M-1, CTX-M-2
and CTX-M-9 clusters are associated with ISEcp1-like insertion
sequences.14 The blaCTX-M-17 and blaCTX-M-19 genes are also
associated with IS903-like elements.14,15 ISEcp1-like insertion
sequences may play a role in the mobilization of the blaCTX-M
genes by a transcriptional mechanism by recognizing a variety of
DNA sequences as right IRs. However, the role of IS903-like
elements in the mobilization process of the blaCTX-M genes has
not yet been demonstrated.
The present work shows once again that novel CTX-M
enzymes with an expanded activity towards ceftazidime through
a single amino acid substitution can be identified from clinical
isolates. Thus, detection of CTX-M enzymes can no longer be
based solely on the resistance phenotypes of clinical isolates
towards ceftazidime and cefotaxime.
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